

CITATION REPORT

List of articles citing

Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma

DOI: 10.1158/1078-0432.ccr-13-1982
Clinical Cancer Research, 2014, 20, 890-903.

Source: <https://exaly.com/paper-pdf/59189021/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
248	The many faces of neuroendocrine differentiation in prostate cancer progression. 2014 , 4, 60		155
247	Aggressive variants of castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 2846-50	12.9	245
246	A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes. 2014 , 10, e1004809		50
245	Defining subgroups of small-cell lung cancer. 2014 , 9, 750-1		3
244	Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. 2014 , 1846, 630-7		25
243	Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle. 2014 , 32, 3360-4		22
242	Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review). 2014 , 45, 1337-44		10
241	Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment. 2015 , 8, 109		20
240	The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. 2015 , 92-103		30
239	Integrative molecular profiling of routine clinical prostate cancer specimens. 2015 , 26, 1110-1118		30
238	Distinct genetic alterations in small cell carcinoma from different anatomic sites. 2015 , 4, 2		24
237	Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. 2015 , 15, 701-11		680
236	Models of neuroendocrine prostate cancer. 2015 , 22, R33-49		35
235	Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. 2015 , 5, 6		37
234	Origins, genetic landscape, and emerging therapies of small cell lung cancer. 2015 , 29, 1447-62		133
233	Genitourinary small cell malignancies: prostate and bladder. 2015 , 11, 479-88		12
232	Overlap of CD44 expression between prostatic small cell carcinoma and acinar adenocarcinoma. 2015 , 46, 554-7		5

231	Polycomb-mediated silencing in neuroendocrine prostate cancer. 2015 , 7, 40		70
230	Frequent MED12 mutations in phyllodes tumours of the breast. 2015 , 112, 1703-8		72
229	Targeting the adaptive molecular landscape of castration-resistant prostate cancer. 2015 , 7, 878-94		83
228	Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. 2015 , 16, e165-72		477
227	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. <i>Clinical Cancer Research</i> , 2015 , 21, 5619-29	12.9	43
226	Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. 2015 , 22, R165-82		39
225	GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes. 2015 , 32, 769-82		37
224	Epithelial-mesenchymal transition in prostatic disease. 2015 , 11, 3197-206		17
223	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. 2015 , 12, 922-36		155
222	[Neuroendocrine prostate cancer]. 2015 , 54, 1779-83		3
221	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016 , 10s1, CMO.Ss34534	1.8	12
220	Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming. 2016 , 231, 2040-7		11
219	p16 overexpression in high-grade neuroendocrine carcinomas of the head and neck: potential diagnostic pitfall with HPV-related carcinomas. 2016 , 469, 277-84		56
218	Hormone resistance and neuroendocrine differentiation due to accumulation of genetic lesions during clonal evolution of prostate cancer. 2016 , 50, 28-36		
217	The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. 2016 , 8, 721-31		80
216	N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. 2016 , 29, 536-547		189
215	Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. 2016 , 16, 1113-1120		5
214	N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. 2016 , 30, 563-577		256

213	NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. 2016 , 138, 927-38		102
212	Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances. 2016 ,		5
211	Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective. 2016 , 16, 1029-37		9
210	Neuroendocrine Tumor of the Ureter: A Zebra Among Horses. 2016 , 2, 204-208		11
209	Expression of Somatostatin Receptor Type 2A and PTEN in Neuroendocrine Neoplasms Is Associated with Tumor Grade but Not with Site of Origin. 2016 , 27, 179-87		6
208	Translational and clinical implications of the genetic landscape of prostate cancer. 2016 , 13, 597-610		45
207	Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2016 , 76, 125-39	4.2	12
206	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. 2016 , 22, 298-305		775
205	Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification. 2016 , 27, 123-35		47
204	Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer. 2016 , 17, 29		20
203	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. 2016 , 22, 369-78		425
202	Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. <i>Clinical Cancer Research</i> , 2016 , 22, 1520-30	12.9	138
201	miR-449a enhances radiosensitivity through modulating pRb/E2F1 in prostate cancer cells. 2016 , 37, 4831-40		25
200	SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. 2017 , 71, 68-78		105
199	The importance of DNA methylation in prostate cancer development. 2017 , 166, 1-15		85
198	Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. 2017 , 355, 78-83		492
197	SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. 2017 , 355, 84-88		491
196	Prostate Cancer Metastasis. 2017 , 33-59		1

195	Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets. 2017 , 471, 155-164	10
194	Circulating tumor cells capture disease evolution in advanced prostate cancer. 2017 , 15, 44	25
193	Neoplasms of the Prostate. 2017 , 1-38	
192	Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology. 2017 , 1, 15	53
191	Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of Missense Mutation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 4693-4703	12.9 39
190	EMT and MET: necessary or permissive for metastasis?. 2017 , 11, 755-769	204
189	Emerging Variants of Castration-Resistant Prostate Cancer. 2017 , 19, 32	86
188	Uncommon Cancers of the Prostate. 2017 , 68-96	
187	RB Loss Promotes Prostate Cancer Metastasis. 2017 , 77, 982-995	47
186	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017 , 77, 1478-1488	4.2 2
185	Targeting androgen-independent pathways: new chances for patients with prostate cancer?. 2017 , 118, 42-53	21
184	[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions]. 2017 , 104, 789-799	3
183	MSH2 Loss in Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 6863-6874	12.9 78
182	Correlation of PSMA-Targeted F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer. 2017 , 15, e65-e68	42
181	The molecular underpinnings of prostate cancer: impacts on management and pathology practice. 2017 , 241, 173-182	33
180	The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. 2017 , 7, 54-71	173
179	Alternative Splicing Provides a Novel Molecular Mechanism for Prostatic Small-cell Neuroendocrine Carcinoma. 2017 , 71, 79-80	2
178	Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. 2017 , 14, 269-283	19

177	Biology and evolution of poorly differentiated neuroendocrine tumors. 2017 , 23, 1-10		109
176	Identification of key pathways and genes with aberrant methylation in prostate cancer using bioinformatics analysis. <i>OncoTargets and Therapy</i> , 2017 , 10, 4925-4933	4.4	5
175	Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. <i>Cancers</i> , 2017 , 9,	6.6	53
174	Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. 2017 , 17, 759		35
173	Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. 2017 , 8, 3724-3745		71
172	Cellular plasticity and the neuroendocrine phenotype in prostate cancer. 2018 , 15, 271-286		153
171	Clinical implications of PTEN loss in prostate cancer. 2018 , 15, 222-234		230
170	Precision Molecular Pathology of Prostate Cancer. <i>Molecular Pathology Library</i> , 2018 ,		1
169	Neuroendocrine Prostate Cancer. <i>Molecular Pathology Library</i> , 2018 , 323-341		
168	Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. 2018 , 74, 146-154		50
167	Clinical and molecular features of treatment-related neuroendocrine prostate cancer. 2018 , 25, 345-351		71
166	p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. 2018 , 21, 260-268		35
165	Molecular Biomarkers in the Clinical Management of Prostate Cancer. 2018 , 8,		10
164	Neuroendocrine tumors of the prostate. <i>Modern Pathology</i> , 2018 , 31, S122-132	9.8	42
163	Long non-coding RNA MIAT in development and disease: a new player in an old game. 2018 , 25, 23		60
162	Epigenetic Regulation in Prostate Cancer Progression. 2018 , 4, 101-115		27
161	The Androgen Signaling Axis and Risk Stratification for High-grade Prostate Cancer. 2018 , 74, 155-156		
160	Molecular model for neuroendocrine prostate cancer progression. 2018 , 122, 560-570		30

159	Autochthonous tumors driven by loss have an ongoing requirement for the RBP2 histone demethylase. 2018 , 115, E3741-E3748	6
158	Anaplastic Lymphoma Kinase Mutation (F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. <i>Clinical Cancer Research</i> , 2018 , 24, 2732-2739	12.9 15
157	Transcriptional Regulation in Prostate Cancer. 2018 , 8,	34
156	Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets. 2018 , 7, R1-R25	18
155	Grading of Neuroendocrine Carcinomas: Correlation of Ga-PET/CT Scan with Tissue Biomarkers. 2018 , 2018, 6878409	6
154	Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification. 2018 , 9, 14723-14737	14
153	Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. 2018 , 362, 91-95	139
152	Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer. 2018 , 41, 627-633	2
151	Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases. 2018 , 42, 1286-1296	15
150	Genetics and biology of prostate cancer. 2018 , 32, 1105-1140	199
149	Molecular Basis of Neuroendocrine Prostate Cancer. 2018 , 387-396	
148	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. 2018 , 7,	35
147	Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans. 2018 , 19, 450	6
146	Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer. 2018 , 8, 28	15
145	Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. 2018 , 8, 69	7
144	Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. 2018 , 246, 244-253	21
143	EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers. 2018 , 1870, 229-238	28
142	Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. 2018 , 79, 151-159	40

141	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. 2018 , 78, 4716-4730		33
140	P53 Gene Mutation Identified by Next Generation Sequencing in Poorly Differentiated Neuroendocrine Carcinoma of the Nasal Cavity. 2019 , 13, 516-522		
139	Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. 2019 , 9,		33
138	Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms. <i>Asian Journal of Andrology</i> , 2019 , 21, 291-295	2.8	18
137	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , 2019 , 25, 6916-6924	12.9	94
136	hnRNPM, a potential mediator of YY1 in promoting the epithelial-mesenchymal transition of prostate cancer cells. <i>Prostate</i> , 2019 , 79, 1199-1210	4.2	9
135	Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma. 2019 , 5, 440-455		15
134	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. 2019 , 33, 1718-1738		29
133	Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. 2019 , 20, 1432-1443		52
132	TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. 2019 , 14, e0213488		13
131	Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play. <i>Cancers</i> , 2019 , 11,	6.6	34
130	N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. 2019 , 18, 11		32
129	Neuroendocrine tumors of genitourinary tract: Recent advances. 2019 , 42, 48-58		5
128	The SOX4/miR-17-92/RB1 Axis Promotes Prostate Cancer Progression. 2019 , 21, 765-776		21
127	Predicting clinical outcome of therapy-resistant prostate cancer. 2019 , 116, 11090-11092		5
126	Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation. 2019 , 17, 25		13
125	Response to olaparib in a germline mutated prostate cancer and genetic events associated with resistance. 2019 , 5,		21
124	If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease. 2019 , 6, 10-25		9

123	Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer. 2019 , 6, 91-98		4
122	Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping. 2019 , 20, 837-842		7
121	Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines. 2019 , 6, IJE20		3
120	Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. 2019 , 76, 89-97		98
119	Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 595-608	12.9	29
118	Paraneoplastic Syndrome Secondary to Treatment Emergent Neuroendocrine Tumor in Metastatic Castration-resistant Prostate Cancer: A Unique Case. 2019 , 17, e56-e60		3
117	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. 2020 , 20, 207-217		4
116	PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3K Inhibitors in Breast Cancer. 2020 , 10, 72-85		73
115	The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy. 2020 , 27, 11-19		4
114	Unraveling cancer lineage drivers in squamous cell carcinomas. 2020 , 206, 107448		10
113	SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer. 2020 , 100, 570-582		12
112	Molecular tracing of prostate cancer lethality. 2020 , 39, 7225-7238		2
111	An overview of advances in multi-omics analysis in prostate cancer. 2020 , 260, 118376		7
110	Emerging role of tumor cell plasticity in modifying therapeutic response. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 228	21	35
109	Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. <i>Prostate</i> , 2020 , 80, 1012-1023	4.2	10
108	Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study. 2020 , 25, 100221		3
107	Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report. 2020 , 20, 171		4
106	Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4143-4153	12.9	27

105	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. 2020 , 44, e15-e29	21
104	Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas. 2020 , 216, 153051	
103	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. 2020 , 9,	2
102	Epigenetic modulations and lineage plasticity in advanced prostate cancer. 2020 , 31, 470-479	43
101	Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. 2020 , 23, 507-516	2
100	Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression. 2019 , 9, 1491	5
99	Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. 2020 , 11, 384	37
98	The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis. 2020 , 126, 26-54	2
97	New insights into small-cell lung cancer development and therapy. 2020 , 44, 1564-1576	18
96	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. 2021 , 11,	8
95	Specificities of small cell neuroendocrine prostate cancer: Adverse prognostic value of TTF1 expression. 2021 , 39, 74.e17-74.e23	2
94	Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma. 2021 , 78, 381-391	3
93	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. 2021 , 157, 103185	15
92	Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 759-774	12.9 9
91	Genomic and phenotypic heterogeneity in prostate cancer. 2021 , 18, 79-92	41
90	Clinical and Biological Features of Neuroendocrine Prostate Cancer. 2021 , 23, 15	17
89	Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. 2021 , 32, 192-210	24
88	Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer. 2021 , 33, 224-232	

87	Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 55	21	6
86	Cross-species identification of PIP5K1-, splicing- and ubiquitin-related pathways as potential targets for RB1-deficient cells. 2021 , 17, e1009354		1
85	A narrative review of individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations?. <i>Translational Andrology and Urology</i> , 2021 , 10, 1553-1561	2.3	1
84	Prominent response to platinum-based chemotherapy in a patient with mutant-neuroendocrine prostate cancer and amplification. 2021 , 4, 216-219		0
83	Transperineal Parallel Biopsy of the Prostate: A New Approach of Tissue Sampling for Precision Medicine. 2021 , 14, 1631-1640		1
82	Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13. 2021 , 112, 2781-2791		2
81	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. 2021 , 12, 3372		3
80	Molecular events in neuroendocrine prostate cancer development. 2021 , 18, 581-596		11
79	An overview of the latest in state-of-the-art murine models for prostate cancer. 2021 , 16, 1349-1364		0
78	Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Étude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. 2021 , 152, 100-115		4
77	Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. 2021 , 39, 1115-1134.e12		19
76	Going beyond Polycomb: EZH2 functions in prostate cancer. 2021 , 40, 5788-5798		5
75	Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. 2021 , 48, 339-347		2
74	Molecular Pathology of Prostate Cancer. 2021 , 14, 387-401		1
73	Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. 2021 , 18, 739-762		5
72	Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer. 2021 , 255, 425-437		2
71	Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance. <i>Cancer Letters</i> , 2021 , 518, 1-9	9.9	6
70	Neuroendocrine cells of the prostate: Histology, biological functions, and molecular mechanisms. 2021 , 4, 25-34		5

69	The Role of RB in Prostate Cancer Progression. 2019 , 1210, 301-318	8
68	Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance. 2019 , 1210, 351-378	32
67	Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. 2020 , 101, 70-79	1
66	EMT and MET: necessary or permissive for metastasis?.	1
65	N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. 2019 , 129, 3924-3940	55
64	Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. 2020 , 130, 1653-1668	56
63	ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming. 2020 , 130, 5924-5941	12
62	The selective PI3K inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. 2017 , 12, e0182852	17
61	Epigenetic changes in fibroblasts drive cancer metabolism and differentiation. 2019 , 26, R673-R688	27
60	PEG10 is associated with treatment-induced neuroendocrine prostate cancer. 2019 , 63, 39-49	15
59	Common ELF1 deletion in prostate cancer bolsters oncogenic ETS function, inhibits senescence and promotes docetaxel resistance. 2018 , 9, 198-214	9
58	Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. 2016 , 7, 78396-78411	36
57	Amplification of MUC1 in prostate cancer metastasis and CRPC development. 2016 , 7, 83115-83133	23
56	Ablating all three retinoblastoma family members in mouse lung leads to neuroendocrine tumor formation. 2017 , 8, 4373-4386	7
55	Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells. 2017 , 8, 84863-84876	17
54	Molecular pathways and targets in prostate cancer. 2014 , 5, 7217-59	68
53	Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. 2015 , 6, 41809-24	29
52	GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. 2016 , 7, 45171-45185	29

51	Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways.. 2020 , 3, 726-741		4
50	Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms.. 2020 , 3, 742-761		2
49	Neuroendocrine differentiation in prostate cancer: key epigenetic players. 2017 , 6, S104-S108		16
48	Understanding cancer lineage plasticity: reversing therapeutic resistance in metastatic prostate cancer. <i>Pharmacogenomics</i> , 2017 , 18, 597-600	2.6	6
47	Molecular aspects of prostate cancer with neuroendocrine differentiation. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016 , 28, 122-9	3.8	10
46	Beta-adrenergic signaling on neuroendocrine differentiation, angiogenesis, and metastasis in prostate cancer progression. <i>Asian Journal of Andrology</i> , 2019 , 21, 253-259	2.8	12
45	Lineage plasticity-mediated therapy resistance in prostate cancer. <i>Asian Journal of Andrology</i> , 2019 , 21, 241-248	2.8	7
44	The regulatory pathways leading to stem-like cells underlie prostate cancer progression. <i>Asian Journal of Andrology</i> , 2019 , 21, 233-240	2.8	12
43	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016 , 10, 1-9	1.8	57
42	Neuroendocrine Tumors of the Prostate and Molecular Features. 2016 , 369-378		
41	Neuroendocrine and Small Cell Carcinomas of the Prostate: Sentinels of Lethal Evolution. 2016 , 191-204		
40	Cabazitaxel for the Treatment of Prostate Cancer. 2016 , 187-214		
39	Cancer Stem Cells. <i>Molecular Pathology Library</i> , 2018 , 99-113		0
38	Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.		
37	TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer.		
36	Small Cell Carcinoma of the Prostate: A Case Report and Review of the Literature. <i>Cureus</i> , 2020 , 12, e70742		0
35	Abl kinase deficiency promotes AKT pathway activation and prostate cancer progression and metastasis.		
34	Narrative review of challenges in the management of advanced neuroendocrine prostate cancer. <i>Translational Andrology and Urology</i> , 2021 , 10, 3953-3962	2.3	1

33	Experimental challenges to modeling prostate cancer heterogeneity. <i>Cancer Letters</i> , 2022 , 524, 194-205	9.9	2
32	ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming.		
31	Chemotherapy and Prostate Cancer. 2021 , 105-118		
30	Androgen action in prostate function and disease. <i>American Journal of Clinical and Experimental Urology</i> , 2018 , 6, 62-77	1.6	28
29	[Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors]. <i>Chinese Journal of Lung Cancer</i> , 2017 , 20, 720-726	0.6	1
28	Expanding therapeutic opportunities for Extra-Pulmonary Neuroendocrine Carcinoma.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	2
27	Superselective Prostate Artery Embolization for Treatment of Severe Haematuria Secondary to Rapid Progression of Treatment-Induced Neuroendocrine Prostate Cancer: A Case Report.. <i>OncoTargets and Therapy</i> , 2022 , 15, 67-75	4.4	
26	BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade.		
25	The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance.. <i>International Journal of Molecular Sciences</i> , 2021 , 23,	6.3	3
24	Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs.. <i>Non-coding RNA</i> , 2021 , 7,	7.1	0
23	loss overrides PARP inhibitor sensitivity driven by loss in prostate cancer.. <i>Science Advances</i> , 2022 , 8, eabl9794	14.3	0
22	Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.. <i>Modern Pathology</i> , 2022 ,	9.8	0
21	Molecular mechanisms underlying the development of neuroendocrine prostate cancer. <i>Seminars in Cancer Biology</i> , 2022 ,	12.7	2
20	The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. <i>Prostate</i> ,	4.2	0
19	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7,	21	4
18	Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components. <i>Cancers</i> , 2022 , 14, 3233	6.6	
17	Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate cancer. <i>Frontiers in Cell and Developmental Biology</i> , 10,	5.7	1
16	Second generation androgen receptor antagonists and challenges in prostate cancer treatment. 2022 , 13,		5

15	Why ARNT Prostate Tumors Responding to Enzalutamide?. 2022 , 12, 2017-2019	0
14	Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells. 2022 , 14, 4626	1
13	Prostate cancer in omics era. 2022 , 22,	0
12	Neoplasms of the Prostate. 1-46	0
11	Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.	0
10	Prostate Cancer. 2022 ,	0
9	CHD6 promotes broad nucleosome eviction for transcriptional activation in prostate cancer cells. 2022 , 50, 12186-12201	0
8	TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer.	0
7	Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer. 2022 , 20,	0
6	Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer. 11,	0
5	Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta-analysis.	0
4	Highly Recurrent IDH1 Mutations in Prostate Cancer With Psammomatous Calcification. 2023 , 36, 100146	0
3	Transcription networks rewire gene repertoire to coordinate cellular reprogramming in prostate cancer. 2023 , 89, 76-91	0
2	High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer. 13,	0
1	Overexpression of RACGAP1 by E2F1 Promotes Neuroendocrine Differentiation of Prostate Cancer by Stabilizing EZH2 Expression. 2023 , 0	0